FIGURE 1.

The timeline of RNA epigenetics. m⁶A was first discovered in the 1970s. In 2011, FTO was identified as an m⁶A demethylase. In 2012, the antibody‐based transcriptome‐wide sequencing method was developed to obtain m⁶A profiling in the human transcriptome. The first FTO inhibitor was found in the same year. Association of m⁶A with cancer began to be reported in breast cancer and lung cancer in 2016, and the cancer types expanded to AML, GBM, HCC, and pancreatic cancer in 2017. Up to now, m⁶A has been found to play critical roles in most cancer types, and inhibitors against more m⁶A regulators are in development. Abbreviations: RNA, ribonucleic acid; m⁶A, N⁶‐methyladenosine; FTO, fat mass and obesity‐associated protein; AML, acute myeloid leukemia; GBM, glioblastoma; HCC, hepatocellular carcinoma